Cart
×
CureDuchenne Ventures invests in Insmed Incorporated to support the development of a next-generation gene therapy with targeted intrathecal delivery and the potential to produce a larger dystrophin construct.
CureDuchenne Ventures announces an investment in Insmed Incorporated to support the development of INS1201, their next generation gene therapy candidate with a targeted delivery approach designed with the potential to address some of the current limitations of gene therapy. Insmed is also exploring the potential of its RNA end-joining technology to deliver larger dystrophin constructs with a goal of ultimately delivering full-length dystrophin protein.
